CD8A and neoplasm: In cancer patients, we previously reported that vaccination with low peptide dose induced tumor antigen-specific CD8 T-cells of enhanced cytotoxicity (i.e., maximal T-cell responses at saturating antigen concentrations), but there was no difference in their functional avidity (i.e., specific T-cell responses when exposed to increasing antigen concentrations) (25).